Tag Archives: BIO

Clarivate Enhances Cortellis CMC Intelligence with Post-Approval Module to Accelerate Regulatory Success


Enhancements enable pharma, biotech and generics companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics 

LONDON, May 2, 2024 /PRNewswire/ — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.

CMC activities account for nearly 18% of the entire R&D budget, emphasizing the importance of optimization and validation. Cortellis CMC Intelligence for post-approval variations enables clients to compare requirements across 64 countries, reducing tracking time and increasing submission rates with organized, timely, and accurate information.

Justin Hubbard, Vice President, Product Management, Life Sciences & Healthcare, Clarivate, said: “This enhancement underscores our commitment to simplifying the complexities of CMC regulatory dossier submissions for our clients. By offering transformative insights, Clarivate accelerates their path to markets and patients. With the ability to efficiently compare regulations across countries for small molecules and biologics, as well as automate CMC regulatory monitoring through user-configured alerts, clients can navigate the process with confidence.” 

With its new module covering both pre- and post-approval documents, Cortellis CMC Intelligence offers comprehensive lifecycle information for drugs and biologics. Serving as a single-platform solution for CMC requirements, it effectively reduces tracking time and unnecessary costs.

About Cortellis CMC Intelligence

Cortellis CMC Intelligence curates and tracks official CMC regulations and local practices for more than 135+ countries, territories and organizations for small molecules and 64 countries, territories and regions for biologics, with pre-and post-approval module coverage. Robust data is available for 25+ product and regulatory-related filters based on eCTD structure, including 6K+ source documents and over 2K links to Cortellis Regulatory Intelligence, providing access to expanded detail and in-depth summaries from experts in local regulatory practices, paired with reference source documents, to offer a complete picture. The addition of a new post-approval module now makes a comprehensive CMC solution with complete lifecycle information for drugs and biologics to increase submission rates and avoid costly delays. To learn more about Cortellis CMC Intelligence, visit here.

About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com 

Media Contact:
Luna Ivkovic
External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

The 2024 Asia Agri-Tech Expo & Forum Demonstrates Taiwan’s Prowess on Smart Farming & Biotechnology, brings in Future and Revolution to Agriculture, Livestock and Aquaculture Industries

TAIPEI, April 15, 2024 /PRNewswire/ — Taiwan is renowned for its engineering prowess, manufacturing most of the components used in smart farming, including IoT sensors, solar panels, drones, robotics, and agriculture technology system integrators bringing revolutionary advancements to the field. The 8th Asia Agri-Tech Expo & Forum (AAT) in Taiwan is not just the leading exhibition but a content-rich event in agriculture industry. According to Informa Markets (UBM Asia Ltd., Taiwan Branch), as one of the hosts of the 2024 Asia Agri-Tech Expo & Forum, the event will take place from June 19th to 21st, 2024, at Tainan, Taiwan, running concurrently with Livestock Taiwan and Aquaculture Taiwan. 

The expo is supported by central and local governments, as well as associations from related agriculture, aquaculture and livestock industries highlighting the expo’s significance in the industry. 

With its extensive exhibitor’s lineup featuring leading companies, the expo offers a comprehensive showcase. The exhibition is differentiated by country and theme pavilions. Main pavilions are:

  • Agriculture Facility Pavilion exhibits premier sustainable greenhouse facilities, environmental control systems, smart agricultural systems, seeds and seedlings, etc.;
  • Smart Aquaculture Pavilion reveals the world’s first oral gender regulation technology, AI-based underwater monitoring and management system, drone application on smart farming for shrimps and fishes, etc.
  • Feed Technology Pavilion has the latest advanced feeds, feed additives, vaccines that provide animal nutrition and immunity enhancement.
  • Livestock Farming Pavilion, the largest pavilion among all, displays all kinds of advanced facilities and houses for livestock farming.  Notable brands include Moba, WEDA, Skiold, SKOV, VDL Jansen, Cloudfarms, Fancom, Kyowa, Frontmatec, Agrisys, AGI, etc.
  • Agri-Machine Pavilion: will showcase the latest research on EV agri-machiney, drones, robotics, just to name a few.

As part of the expo, a series of professional conferences will be held, addressing key issues and emerging trends in agriculture, livestock, and aquaculture, which include:

  • Innovative Aquaculture Management Seminar
  • Forum of Taiwan Swine – Precision Farming and Management
  • Forum of Advanced Poultry House
  • The 2nd edition of Precision Prevention Medication for Animals Forum
  • EV Agri-Machinery and Technology Seminar

Attendees can expect valuable and practical insights, and networking opportunities from industry experts and thought leaders.

The 3-in-1 event not only provides a one stop sourcing platform but also cooperation opportunities for international players. “The world is now in the middle of its biggest agricultural revolution. As an agricultural research and development leader since the 1960’s, Taiwan is an early adopter and innovator in agricultural technologies. With the prowess on IT manufacturing, bio-research achievements, and the know-how on working with the humidity of the tropical climate”, said Ms. Sabine Liu, General Manager of the organizer, “Taiwan is set to take a significant role for many of agriculture changes. In addition, located within two hours from mainland China’s main cities and four hours from Southeast Asia countries, Taiwan is the perfect base for companies looking for partners to enter mainland China or other parts of Southeast Asia markets.” 

For any interest or inquiries of ASIA AGRI-TECH EXPO & FORUM, please visit the official website at: https://www.agritechtaiwan.com

The 8th edition of Asia Agri-tech Expo & Forum, Livestock Taiwan and Aquaculture takes place from June 19-21, 2024 in Tainan, Taiwan.
The 8th edition of Asia Agri-tech Expo & Forum, Livestock Taiwan and Aquaculture takes place from June 19-21, 2024 in Tainan, Taiwan.

A series of professional conferences will be held, addressing key issues and emerging trends in the exhibition.
A series of professional conferences will be held, addressing key issues and emerging trends in the exhibition.

Industry leaders, experts, and stakeholders come from around the world together. Photo taken from the opening ceremony of 2023.
Industry leaders, experts, and stakeholders come from around the world together. Photo taken from the opening ceremony of 2023.

Industry leaders, experts, and stakeholders come from around the world together. Photo taken from the opening ceremony of 2023.
Industry leaders, experts, and stakeholders come from around the world together. Photo taken from the opening ceremony of 2023.

The exhibition offers a comprehensive showcase, products and services.
The exhibition offers a comprehensive showcase, products and services.

About the show

The 8th exhibition will be themed “Future” through “Sustainable, Eco-friendly, Innovative” agricultural technologies. It will showcase the latest agricultural technologies and achievements, including electric agri-machinery, environmental control greenhouses, bio-fertilizer, feed additives, animal health, poultry and pig farming equipment, seafood processing equipment, cold chain technologies, preserve technology, and more.

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. We provide marketplace participants around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, targeted digital services and actionable data solutions. We connect buyers and sellers across more than a dozen global verticals, including Agriculture, Livestock, Aquaculture, Pharmaceuticals, Food, Medical Technology and Infrastructure. As the world’s leading market-making company, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com

Join Taipei City’s Thriving Health Industry: Registration for “Win A Greater Health” Pitch Contest Starts Now!

TAIPEI, July 18, 2023 /PRNewswire/ — The Taipei City Government’s Department of Economic Development is taking proactive steps to attract international startups and foster collaboration with local businesses through its “Talent Exchange Program”. In line with this initiative, they have established the “Taipei Entrepreneurs Hub (TEH)” to cultivate a vibrant international community of entrepreneurs in the heart of Taipei. In 2023, the spotlight is on the health industry, and the department is delighted to announce the forthcoming “Win A Greater Health” international online startup pitch contest. Registration is now open until September 15, 2023, Taipei time (UTC+8). International teams specializing in digital health fields are welcomed to participate.

The department places great importance on attracting international startup teams with key technologies and research capabilities to facilitate the cooperative transformation and upgrade of local industries. This has always been a crucial industrial goal for the city government. Additionally, harnessing the power of innovation and entrepreneurship to drive city diplomacy is a significant driving force. Therefore, in recent years, the department has actively connected global startup ecosystem resources through TEH, organizing various networking events across different industries and time zones, creating the most resource-rich and comprehensive entrepreneurial community. The ultimate goal is to welcome international entrepreneurs from around the world to establish their presence in Taipei.

This year, the international startup pitch contest, in collaboration with TEH, the Taiwan Digital Health Industry Development Association, BE Health Ventures, and the Taipei Medical University BioMed Accelerator, welcomes international startup teams to participate. The competition encourages teams to develop Taiwan market expansion plans with a focus on implementing their goals in Taipei City. The winning teams will not only receive one international round-trip ticket from anywhere to Taipei to attend the Demo Day presentation but also enjoy customized matchmaking sessions and business itineraries during their stay in Taipei. Selected teams will have diverse opportunities for technological connections, collaborations, and interactions with businesses and venture capital firms in Taipei.

In addition to organizing the competition, the city government has established StartUp@Taipei office and Inves Taipei office to support startups from around the world in settling in Taipei. The ultimate goal is to make Taipei City a partner for international talents and collaborate to develop more business opportunities.

For more information and registration details for the online competition, you can visit the official Facebook page or LinkedIn page, or contact the organizing company Everiii Consulting CO., Ltd. at (+886 2) 33435456 ext. 806, Ms. Kuo.

Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023

Enhanced sequencing capabilities offer opportunity to accelerate breakthroughs in life science research

SAN JOSE, Calif., Dec. 30, 2022 /PRNewswire/ — Complete Genomics Inc(https://completegenomics.mgiamericas.com/), a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting at Biotech Showcase™ 2023, taking place in San Francisco at the same time as the JP Morgan healthcare conference. Registered attendees can view Complete Genomics presentation live and through 24×7 on-demand access if scheduling does not allow viewing during the main event week.

Complete Genomics offers complete high throughput sequencing instrumentation and related products, including sample extraction, library prep, automation system, sequencing platforms, and bioinformatics. Rade Drmanac, PhD, Chief Scientific Officer, will provide an overview of the complete suite of high throughput sequencing instruments and related products. The live presentation will be on:

Date: Monday, January 9
Time: 16:30pm PST
Venue: Hilton San Francisco Union Square Hotel
Room: Franciscan D

“Dating back to as early as 2006, we have been at the forefront of life science innovation and continue to redefine sequencing possibilities through our innovative DNBSEQTM technology,” said Dr. Drmanac. “Over the years, our massively parallel sequencing (MPS) and sample processing automation products have empowered countless customers and partners around the world in their scientific research and clinical applications. As we aim to broaden our reach into the US market, we look forward to attending Biotech Showcase™ to demonstrate our enhanced sequencing capabilities and how we can help our partners accelerate breakthroughs in life science and healthcare with this state-of-the-art technology.”

Complete Genomics sequencing platforms are based on DNBSEQTM, sample extraction, library prep, automation system, and bioinformatics to the US market and beyond. In August 2022, its DNBSEQ-G400C* sequencer was released in the US with immediate adoption in several customer labs and partnerships with various life science companies.

Moreover, Complete Genomics will launch at Biotech Showcase the “Empowerment Program America”, which will bring choice to sequencing by collaborating with researchers to develop grant proposals.

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry’s largest gatherings and busiest weeks.

“We are delighted that Complete Genomics will be joining us in San Francisco and presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 15th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT COMPLETE GENOMICS

Complete Genomics, a subsidiary of MGI Tech Co., Ltd., is a global life science company offering lab automation and a comprehensive high throughput sequencing product portfolio. Founded in 2006 and currently located in San Jose, California, Complete Genomics maintains a demo lab and full supply center with all of its sequencers and lab automation equipment on display. Complete Genomics released its first next-generation sequencing system, the DNBSEQ-G400C* platform in the US, in August 2022. For all sequencer specifications, please visit the Complete Genomics website.

Follow Complete Genomics on Twitter at @ Complete Genomics and Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase

*Unless otherwise informed, StandardMPS and CoolMPS sequencing reagents, and sequencers for use with such reagents are not available in Germany, Spain, UK, Sweden, Belgium, Italy, Finland, Czech Republic, Switzerland, Portugal, Austria, and Romania. Unless otherwise informed, StandardMPS sequencing reagents, and sequencers for use with such reagents are not available in Hong Kong. No purchase orders for StandardMPS products will be accepted in the USA until after January 1, 2023.

Cision View original content:https://www.prnewswire.com/news-releases/complete-genomics-to-present-its-multiple-innovative-sequencing-platforms-at-biotech-showcase-2023-301711121.html

NeuroXess Shares Latest Breakthoughs in Life Sciences at Sequoia Talk

SHANGHAI, Nov. 3, 2022 /PRNewswire/ — Peng Lei, CEO of NeuroXess, a Sequoia firm, was invited to participate in Sequoia China’s Sequoia Talk Series on “The Compound Interest of Innovation” at which he shared his knowledge of and experience with the latest technological innovations in the field of brain science. As the founder of a start-up firm, Peng noted that we are now in an era of technology-led entrepreneurship. Crossing the border from the internet to the realm of life sciences, he said that it behooves one and all to keep making future-oriented, innovative, ground-breaking discoveries and putting them into practice.

Rome was not built in a day. Influential innovations are the rewards for those who continuously invested in this sector. At the first Brain Sciences Theme Forum of 2022 World Artificial Intelligence Conference (WAIC) that just took place in September, NeuroXess launched its first integrated cranial parietal semi-implantable medical-grade brain-computer interface (BCI), a high-frequency EEG signal processor bundled together with a software and algorithm cloud platform. Peng said that the company has built up considerable expertise in related technologies and products. In his presentation on the company’s core technology, he noted, “Our cortical electrodes and flexible deep electrodes featuring MEMS micro and nano technology are greatly superior to traditional medical devices both in terms of technical indicators and the size and flexibility of the electrode.”


In addition, NeuroXess is using silk protein as the wrapping material to assist the implantation of the electrodes. Peng said that this approach reduces the trauma and damage to the brain that can take place during the implantation process, while the material itself is more easily degradable and is a safer implantation aid. He continued, “At present, with our BCI devices, chips for signal collecting and processing are able to support channel addressing for a 16,000-channel chip and the simultaneous acquisition of 2000 channels. This is the feature that really sets our chips apart.”

Peng said that the company’s newly-released algorithm cloud platform facilitates leveraging the capabilities of the Internet, AI, and cloud computing to analyze digital EEG signals, enabling the continuous overlay and sharing of algorithms and data on the cloud. He described it as similar to Tesla’s self-driving function: the more cars there are on the road, the more accurate the L4 algorithm will be. Eventually, we will form a closed loop in the EEG algorithm, and the more people use it, the more accurate our final decoding algorithm will become.

From September to December, 16 senior investors from Sequoia China and 40+ entrepreneurs from companies at the forefront of innovation will be invited to discuss the intersection of technology and healthcare, and discover and put into practice the breakthrough innovations that can guide our future by examining the best examples of existing achievements.

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

  • The transposon technology development following the customized CRISPR/Cas system for bacteriophage
  • 2nd Generation technology of Robot Bacteriophage

BOSTON and SEOUL, South Korea, Oct. 18, 2022 /PRNewswire/ — iNtRON Biotechnology (“iNtRON”, www.intodeworld.com) has announced today that the Company has established the 2nd generation technology of Robot Bacteriophage development. The random transposon mutagenesis technology can be now applied into the bacteriophage genome in addition to the previously announced the customized CRISPR/Cas system for the bacteriophage engineering improvement. In virtue of the progress, non-essential genes can be identified in the bacteriophage genome, and a gene transfer for granting additional functions to the target site along with genome size control can be done much easily.

iNtRON pursues to not only neutralize viruses using bacteriophages based on PHAGERUS® but also apply PHAGERIA® and PHAGERIARUS® platform technology for the development of immunotherapeutic agents. To enable this, the Company requires to secure more advanced Robot Bacteriophage technology in order to freely design and produce the bacteriophage genome as desired.

Following the previously developed the ‘REVERSE’ genetics technology, the customized CRISPR/Cas System for bacteriophages, the technology developed this time is a ‘FOWARD’ genetics technology, which facilitate to find and remove non-essential genes in the bacteriophages. That is, iNtRON has secured the 2nd generation platform technology that can develop a Robot Bacteriophage with desired characteristics by introducing wanted genes into the retained empty spaces from the removed non-essential genes.

Dr. SON, Jee Soo, BD department head of iNtRON said “This is the first case of utilizing random mutagenesis to test bacteriophage gene function, and I think it has great significance in that High-throughput Screening (HTS) became possible through the modified and optimized random mutagenesis technology developed this time that uses the conventional transposon used for bacteria, but iNtRON adds the technology of an experimental method to select mutation-induced improved bacteriophage.”

In this regard, the Company official has shared that iNtRON plans to keep upgrading and accelerating the technology so it could improve genes regardless of its size and gradually expand the types and categories of the improved bacteriophages by selection and removal of the non-essential genes from various natural bacteriophages isolated by iNtRON.

Mr. YOON, Kyung Won, CEO of iNtRON said “As we believe the ‘modified random mutagenesis’- based platform technology developed this time can be utilized universally in PHAGERUS® for the antiviral agents development, and PHAGERIA® and PHAGERIARUS® for the anticancer and immunomodulatory agents development, the Company plans to expand the development field and target area continuously.”

About iNtRON Biotechnology, Inc.

iNtRON is a leader in bacteriophage-based technology with aim to develop and investigate into the ‘Immune & Immunotherapeutics’ market. While pursuing global research and business development (R&BD) investments since their foundation and accelerated development after entering its IPO in KOSDAQ, the company honed in on innovating BIO New Drugs by developing various ‘First-in-Concept’ bio-drugs and conducting clinical studies in phases. The Company is committed to development of innovative innovation in the infectious diseases and ‘Immune & Immunotherapeutics’ area.

About iNtODEWORLD, Inc.

iNtRON has established its wholly owned US subsidiary, iNtODEWORLD, Inc. in 2017. iNtODEWORLD was initially registered in Delaware and the headquarter office is currently located in Boston. iNtODEWORLD provides news, updates and platform development progresses of iNtRON to its potential global partners and collaborators along with its own R&BD works in the US.

Contact Us

YOON, Kyung Won (Kevin) / CEO, Vice President / kwyoon@intron.co.kr
SHIN, Tae Kyu (TK) / BD Team Leader / tkshin@intron.co.kr
BD Team / partner@intron.co.kr
www.intodeworld.com

iNtRON Biotechnology, Inc.

#708, 148, Sagimakgol-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do, Republic of Korea

iNtODEWORLD, Inc.

1500 District Avenue, Suite 2097, Burlington, MA 01803, USA

it is iNtRON.

Cision View original content:https://www.prnewswire.com/news-releases/intron-developed-advanced-bacteriophage-engineering-platform-technology-based-on-modified-random-mutagenesis-301651571.html

Source: iNtRON Biotechnology, Inc.

Yunji’s Technology-empowered Private Label SUYE Celebrates Its 12th Anniversary

HANGZHOU, China, Aug. 1, 2022 /PRNewswire/ — Yunji Inc. (“Yunji” or the “Company”) (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced the celebration of its private-label skin care brand SUYE’s 12th anniversary. SUYE generated over 21 million RMB sales of its high-quality products during its anniversary month of July, including its newly launched GHK-Cu (Copper Glycyl-histidine-tripeptide) multi-effect repairing freeze dried set and polypeptide anti-wrinkle kit. In line with its 12-year development as a socially-conscious brand, SUYE actively participates in charitable activities and contributes to social welfare.

SUYE provides customers with effective and professional products by leveraging its cutting-edge biotechnology and by partnering with top-tier international companies in product development. Since 2016, SUYE has collaborated with a Netherlands-based company, and their joint research revealed the effective anti-aging properties of peptides. Building on this discovery, SUYE has invested extensively in peptide research and developed a wide variety of products that utilize their unique properties. SUYE has gradually implemented product-development strategies that enable its customers to better meet their skin care needs, incorporating professional ingredients typically only utilized in medical aesthetics into its product line. During 2021, SUYE further embraced this approach by launching skin care products that contain ingredients used in mesotherapy treatments. With a research philosophy that emphasizes innovation and application of the latest advances in medical aesthetics, Yunji is committed to providing its customers with safe and effective skincare solutions.

In addition to these successful product developments, SUYE has further committed itself to philanthropic causes. SUYE has partnered with nonprofit dental care provider Future Smile Charitable Foundation, Alibaba’s public welfare group, and other organizations to launch its “Donate for Love” welfare initiative. Donate for Love provides free medical examinations and reconstructive surgery for patients with head and facial deformities, allowing them to smile more confidently.

Shanglue Xiao, Founder and CEO of Yunji, commented, “We are excited by the enthusiastic reception SUYE’s biotechnology-infused products have received from our users. As one of Yunji’s beauty brands’ key private labels, SUYE is synonymous with high-quality products that deliver innovative and effective anti-aging solutions.”

Safe Harbor Statements

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident,” “potential,” “continue” or other similar expressions. Among other things, the quotations from management in this announcement, as well as Yunji’s strategic and operational plans, contain forward-looking statements. Yunji may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Yunji’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Yunji’s growth strategies; its future business development, results of operations and financial condition; its ability to understand buyer needs and provide products and services to attract and retain buyers; its ability to maintain and enhance the recognition and reputation of its brand; its ability to rely on merchants and third-party logistics service providers to provide delivery services to buyers; its ability to maintain and improve quality control policies and measures; its ability to establish and maintain relationships with merchants; trends and competition in China’s e-commerce market; changes in its revenues and certain cost or expense items; the expected growth of China’s e-commerce market; PRC governmental policies and regulations relating to Yunji’s industry, and general economic and business conditions globally and in China and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Yunji’s filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and Yunji undertakes no obligation to update any forward-looking statement, except as required under applicable law.

About Yunji Inc.

Yunji Inc. is a leading social e-commerce platform in China that has pioneered a unique, membership-based model to leverage the power of social interactions. The Company’s e-commerce platform offers high-quality products at attractive prices across a wide variety of categories catering to the day-to-day needs of Chinese consumers. In addition, the Company uses advanced technologies including big data and artificial intelligence to optimize user experience and incentivize members to promote the platform as well as share products with their social contacts. Through deliberate product curation, centralized merchandise sourcing, and efficient supply chain management, Yunji has established itself as a trustworthy e-commerce platform with high-quality products and exclusive membership benefits, including discounted prices.

For more information, please visit https://investor.yunjiglobal.com/

Investor Relations Contact

Yunji Inc.
Investor Relations
Email: Yunji.IR@icrinc.com
Phone: +1 (646) 224-6957

ICR, LLC
Robin Yang
Email: Yunji.IR@icrinc.com
Phone: +1 (646) 224-6957

Cision View original content:https://www.prnewswire.com/news-releases/yunjis-technology-empowered-private-label-suye-celebrates-its-12th-anniversary-301596864.html

Source: Yunji Inc.

The Taiwanese Startup Mindtronic AI Opens the Way to the Future of Mobility With Meta-Service Ecosystem

The Taiwanese start-up marks its fifth CES Innovation Award win since 2018 with its auto technology.

LAS VEGAS, July 29, 2022 /PRNewswire/ — Mindtronic AI (https://www.mindtronicai.com/), a Taiwan-based startup, unveils the world’s first Meta-Service, a biometric sensing technology that provides instant access to any visible object in the real world. This technology ushers in the future of mobility, and celebrates the company’s fifth CES Innovation Award win since 2018. Mindtronic AI will be showcasing its technology at the Taiwan Tech Arena Pavilion at 2022 CES.

Auto technology to monitor and analyze

Working with telecom companies, rental cars, and car manufacturers to deploy this new connectivity, the arrival of the Meta-Service will see the creation of a new type of data in the form of a user’s instant interest. This impacts not just the automotive industry, but also consumer behavior in general in response to advertising. 

Mindtronic AI has partnered up with V2X Network, an autonomous transaction platform for the mobility ecosystem, allowing its Meta-Service to learn drivers’ patterns via its biometric sensing technology. It precisely predicts the driver’s current interest and helps connect the Internet and local services into one combined metaverse. With its focus on activation only upon interest, users are also not at the risk of being overwhelmed.

“Originally we just made our biometric sensing technology on the road for monitoring driver’s drowsiness. Today we push it further to infer driver’s interest by analyzing their behaviors”, said Sharon Jiang, CEO of Mindtronic AI. “The service of future mobility is transformed from physical mobility to data mobility, and the car becomes more intelligent than ever to provide passenger services proactively!” 

Creating the future in flying

In addition to the Meta-Service, Mindtronic AI has been working on its automotive-grade designs built with edge-based AI deep learning for both cockpit design and sub-systems. The partnerships between the company and many automotive original equipment manufacturers (OEMs) and tier-1 suppliers in the smart cockpit and advanced driver-assistance system (ADAS) have allowed Mindtronic AI to continue refining its research and products with a view on the experiencing the future today.

The potential of a 3D immersive bio-interactive UI is clear, with Mindtronic AI’s NOAH system offering a 3D digital cluster with embedded facial recognition and driving monitoring system (DMS). This can be further enhanced with a cockpit upgraded with an AI domain controller under the DIRIGENT system, and at the center of it all is the DMX system, an ADAS that can ensure safety for all. The company is also working on Omni-Fleet, its cloud intelligence system designed for preventative safety at the fleet level.

Interested partners looking to collaborate with Mindtronic AI in the new ecosystem of the Meta-Service or its other innovations can reach out to Mindtronic AI via info@mindtronicai.com.


About Mindtronic AI 

Mindtronic AI is an A.I. partner for automobiles and provides solutions and design services in areas like in-cabin sensing, smart cockpit, ADAS, and fleet management. The company was founded in 2017, and had won CES Innovation Awards five times. In 2021, the company was also selected by the German Trade Office as the best start-up of Taiwan and one of the top-3 in Asia.  

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/the-taiwanese-startup-mindtronic-ai-opens-the-way-to-the-future-of-mobility-with-meta-service-ecosystem-301595913.html

Vela Diagnostics Develops PCR-based Test for Detecting Monkeypox Virus

SINGAPORE, July 26, 2022 /PRNewswire/ —  Vela Diagnostics announced that it has developed a PCR test kit to detect the monkeypox virus (MPXV), for research use only (RUO).

The ViroKey® MPXV PCR Test allows for the prompt, in vitro detection of MPXV DNA from human skin lesion specimens. It is compatible with common real-time PCR cyclers, such as the Rotor-Gene Q and Applied Biosystems 7500 series platforms. In silico testing shows that the assay is specific for MPXV and has no cross-reactivity with other orthopoxviruses.

“We worked closely with our customers to develop a test that is specifically designed to meet their requirements, making sure that they have a monkeypox-specific assay, with maximum flexibility to choose between manual and automated workflows depending on the number of samples they receive,” said Dr Charlie Lee, Head of Research and Development at Vela Diagnostics.

The monkeypox outbreak has been declared a global health emergency by the World Health Organization (WHO), with over 16,000 cases worldwide. The mode of transmission is thought to be close, sustained physical contact with other people who have monkeypox. The WHO has requested for all countries to provide testing for any individuals that meet the suspected case definition, and to immediately notify it in the case of positive laboratory results.

“Throughout the COVID-19 pandemic, we have worked closely with various testing labs across the globe. We responded quickly to the monkeypox epidemic by allowing research partners and laboratories to offer timely and accurate monkeypox testing,” said Sam Dajani, CEO of Vela Diagnostics and Chairman of the Board. “We have already released the first few batches of kits, and they are being evaluated by our customers globally. We are committed to increasing testing capacity of monkeypox in hopes of containing the spread of the virus.”

For more information; including the IFU, please contact us.

About Vela Diagnostics

Vela Diagnostics is a leading provider for integrated IVD system solutions, from sample to result. VELA’s test solutions utilize the automated SentosaTM platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology.

All Sentosa products listed above are by Vela Diagnostics. For more information, visit www.veladx.com. All other product names, trademarks and logos are the property of their respective owners.

Cision View original content:https://www.prnewswire.com/news-releases/vela-diagnostics-develops-pcr-based-test-for-detecting-monkeypox-virus-301593161.html

IFN Neurologic and MetaCell Partner to Launch the IFN Neurologic Affiliate Program

CAMBRIDGE, Mass., and PERTH, Australia, June 28, 2022 /PRNewswire/ —

Summary

The Institute of Functional Neuroscience, a world leading treatment and rehabilitation centre utilising the latest technologies in neuroplasticity research, and MetaCell, an innovative life science software company specialised in cutting-edge research software for major pharma, biotech, and academic institutions, have partnered to launch IFN Neurologic. This application will help clinicians to better serve patients with neurological disorders and provide treatments in the functional neuroscience domain. The application has been piloted with a limited number of clinics in 2021/2022, and now is made available to clinics and patients worldwide.

IFN Neurologic is an innovative application to help clinicians better serve patients with neurological disorders and provide treatments in the functional neuroscience domain
IFN Neurologic is an innovative application to help clinicians better serve patients with neurological disorders and provide treatments in the functional neuroscience domain

Affiliate Program 

Affiliate clinics will use for the first time IFN Neurologic to perform restorative neuroplasticity interventions on their patients at their own clinic. The affiliate program includes a comprehensive education program accredited by IFN (Institute of Functional Neuroscience) and AICN (Australian Institute of Clinical Neuroscience), all the necessary hardware/software, and access to the IFN Neurologic platform.

The team

Dr. Randy Beck, PhD, Director of the IFN, said: “We’re excited to be launching this new application in partnership with MetaCell. With this new software that requires no installation and can be reached from any web browser in the world, we now have the ability to rapidly scale up our diagnostic processes and reach more patients around the world at the click of a button.”

Giovanni Idili, COO of MetaCell, added: “We are very proud to work with Dr. Beck and provide IFN with a solution that ultimately allows the organisation to help a much greater number of patients at the same outstanding level of service, and we look forward to partnering with many more clinical innovators using our unique approach to custom software development in concert with our clinical neuroscience platforms.”

About IFN

The Institute of Functional Neuroscience (IFN) utilises the latest in neuroplasticity and neuroscience research to develop treatment approaches aimed at improving brain and nervous system performance of patients with a wide range of conditions including migraines, seizure disorders, strokes, attention deficit disorders, obsessive compulsive disorder, developmental coordination delay, vertigo, depression, learning and developmental disorders, concussion syndromes and autism.

About MetaCell

MetaCell is a life science-focused software company composed of scientists and software engineers, with deep domain expertise in computational neuroscience, molecular biology, data science, and enterprise-grade online software development. Their solutions have been trusted for over a decade by some of the world’s largest pharmaceutical companies and leading research institutions in the USA, UK, Australia, Canada, and Europe, including Biogen, Pfizer, Eisai, Salk, UCL, Mount Sinai, UCSD, Yale, Princeton, and many more.

Contact details

IFN Neurologic: https://ifnneurologic.com/ | +61 (08) 6254 2282 | affiliateprogram@ifnneurologic.com
IFN: https://ifn.net.au | +61 (08) 6254 2282 | info@ifn.net.au 
MetaCell: https://metacell.us/ | US +1 617-286-4832 | UK +44 1865 648684 | info@metacell.us